Glucotrack Announces Enrollment for Clinical Study
Glucotrack, Inc. (NASDAQ: GCTK), a pioneering medical technology company, has recently made a significant announcement regarding the start of patient enrollment for its human clinical study focused on a novel continuous blood glucose monitor (CBGM). This groundbreaking device is aimed at enhancing the management of diabetes for both type 1 and type 2 patients, with results expected within a short timeframe of approximately six to eight weeks.
Innovative Approach to Blood Glucose Monitoring
The CBGM developed by Glucotrack differentiates itself from traditional continuous glucose monitors by measuring glucose levels directly from the blood instead of interstitial fluid. This capability allows for real-time readings that eliminate the lag often associated with interstitial measurements, providing users with immediate feedback on their glucose levels. The device is designed as a long-term implantable solution, intended for three years of accurate blood glucose monitoring without any need for external components. This makes it a convenient and less intrusive option for users managing diabetes.
Details of the Clinical Study
This single-arm study will be conducted in a hospital setting, where a CBGM sensor will be implanted intravascularly for a duration of four days. Participants will consist of individuals diagnosed with diabetes mellitus who require consistent glucose monitoring and intensive insulin therapy. Throughout the study, these participants will undergo a series of controlled meal and glucose challenges to assess the performance of the monitor.
Expert Oversight in Clinical Research
The clinical study is being led by Dr. Alexandre Abizaid, a distinguished specialist in interventional cardiology. Dr. Abizaid is affiliated with the Instituto do Coração in São Paulo, Brazil, and holds a Visiting Professor position at Columbia University Medical Center in New York City. His contributions to the Cardiovascular Research Foundation in New York have made him a globally regarded expert, particularly in conducting innovative clinical studies.
Positive Outlook for the Future
Reflecting on this milestone, Paul V. Goode, PhD, the President and CEO of Glucotrack, expressed his enthusiasm for the advancements made in their preclinical program. He stated, "We are thrilled to reach this significant point in the evolution of our CBGM. We anticipate that this early feasibility study will showcase our device's potential to provide a unique and greatly improved approach to glucose monitoring for those living with diabetes." The excitement surrounding this new innovation from Glucotrack reflects a commitment to enhancing the quality of life for diabetes patients.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) focuses on creating and commercializing novel diabetes management technologies. The company is currently innovating a long-term, implantable continuous blood glucose monitoring system to support individuals managing diabetes. With a sensor designed for a longevity of three years and minimal calibration required, Glucotrack's CBGM aims to redefine continuous glucose monitoring methods.
Frequently Asked Questions
What is Glucotrack's new device designed to do?
Glucotrack's new continuous blood glucose monitor aims to provide real-time glucose level readings directly from the blood for diabetes patients.
Who is conducting the clinical study?
The clinical study is led by Dr. Alexandre Abizaid, an expert in interventional cardiology.
How long is the sensor implanted during the study?
The sensor will be intravascularly implanted for a period of four days during the study.
How will the data from the study be used?
The data collected will assess the performance and reliability of Glucotrack’s continuous blood glucose monitor.
What is the anticipated timeline for results?
Results from the clinical study are expected to be available within six to eight weeks after enrollment.
